For a better user experience please update your browser or use Chrome or Firefox browser.
Utilities
Publication detail
HomeStudy on the economic impact of supplementary protection certificates, pharmaceutical incentives and rewards in Europe
Final report
Publication metadata
In this study, we utilise a unique, new dataset to assess the economic impact of supplementary protection certificates (SPC’s) and the pharmaceutical incentives and rewards in the EU. We develop a measure called the ‘Effective protection period’. It reflects the time that elapses from a medicinal product obtains a marketing authorisation until the last measure of protection on it expires; this could be the original patent, an SPC or one of the other incentives and rewards in the pharmaceutical legislation. We find that 45% of the medicinal products in our dataset have obtained an SPC in at least one of the European countries. We find that the SPC has added years to the effective protection period for those innovator products where the SPC is the last measure of protection to expire. While the protection for medicinal products in the EU is amongst the strongest in the world, we find that for the medicinal products in our dataset the average effective protection period has decreased by approximately two years from 15 to 13 years since 1996 (with variations in individual cases). We find that a longer effective protection period stimulates research and development into new medicinal products. We also find that it delays an average price drop of approximately 50 pct. following the entry of generics. We find that companies choose to launch more medicinal products faster in larger and wealthier countries. Hence, not all new products are made available in all European countries and not at the same time.
- Published:
- Corporate author(s): Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs (European Commission)
- Themes: Pharmaceutical and cosmetics industry
- Subject: drug surveillance , economic consequence , European Union , market access , medicinal product , pharmaceutical industry , pharmaceutical legislation , pharmaceutical product , report
|
PDF
|
|||
| ISSN | ISBN 978-92-79-68050-2 | DOI 10.2873/886648 | Catalogue number ET-02-17-396-EN-N |
- Released on EU publications website:
Document viewer
Note:
The publication cannot be displayed in the document viewer. Open web version
You may access it from: Download and languages